RESUMEN
Although amphotericin B-azole combination therapy has traditionally been questioned due to potential antagonistic interactions, it is often used successfully to treat refractory invasive aspergillosis. So far, pharmacodynamic (PD) interactions have been assessed with conventional in vitro tests, which do not mimic human serum concentrations and animal models using limited doses. We therefore simulated the human serum concentration profiles of amphotericin B and voriconazole in an in vitro dialysis/diffusion closed pharmacokinetic-pharmacodynamic (PK-PD) model and studied the pharmacodynamic interactions against an azole-resistant and an azole-susceptible Aspergillus fumigatus isolate, using Bliss independence and canonical mixture response surface analyses. Amphotericin B dosing regimens with the drug administered every 24 h (q24h) were combined with voriconazole q12h dosing regimens. In vitro PK-PD combination data were then combined with human PK data by using Monte Carlo analysis. The target attainment rate and the serum concentration/MIC ratio were calculated for isolates with different MICs. Synergy (20 to 31%) was observed at low amphotericin B-high voriconazole exposures, whereas antagonism (-6 to -16%) was found at high amphotericin B-low voriconazole exposures for both isolates. Combination therapy resulted in 17 to 48% higher target attainment rates than those of monotherapy regimens for isolates with voriconazole/amphotericin B MICs of 1 to 4 mg/liter. Optimal activity was found for combination regimens with a 1.1 total minimum concentration of drug in serum (tCmin)/MIC ratio for voriconazole and a 0.5 total maximum concentration of drug in serum (tCmax)/MIC ratio for amphotericin B, whereas the equally effective monotherapy regimens required a voriconazole tCmin/MIC ratio of 1.8 and an amphotericin B tCmax/MIC ratio of 2.8. Amphotericin B-voriconazole combination regimens were more effective than monotherapy regimens. Therapeutic drug monitoring can be employed to optimize antifungal combination therapy with low-dose (≤0.6 mg/kg) amphotericin B-based combination regimens against resistant isolates for minimal toxicity.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Azoles/uso terapéutico , Polienos/uso terapéutico , Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Antifúngicos/farmacocinética , Azoles/farmacocinética , Interacciones Farmacológicas , Monitoreo de Drogas , Farmacorresistencia Fúngica , Quimioterapia Combinada , Semivida , Humanos , Pruebas de Sensibilidad Microbiana , Modelos Estadísticos , Método de Montecarlo , Polienos/farmacocinética , Voriconazol/administración & dosificación , Voriconazol/uso terapéuticoRESUMEN
OBJECTIVES: The aim of the present study was to evaluate the effects of amphotericin B (AMB) on clinical isolates of Aspergillus flavus. METHODS: MICs of both standard AMB and liposomal AMB (L-AMB) were determined using a broth dilution method for seven isolates of A. flavus. AMB MICs were also determined using the Etest. The activity of the polyene was then investigated in a murine model of systemic aspergillosis in which animals were infected intravenously, treated intravenously with several doses of the polyene (1-10 mg/kg/day) and observed for survival. RESULTS: Broth dilution AMB, broth dilution L-AMB and Etest AMB MICs ranged from 0.5 to 2.0 mg/L, 0.06 to >16 mg/L and 1.0 to >32 mg/L, respectively. There were two isolates for which all doses were effective at prolonging the survival. Their AMB MICs were ≤1.0 mg/L, regardless of the method/drug formulation utilized for testing. There were four isolates for which no regimen was effective. Their broth dilution AMB, broth dilution L-AMB and Etest AMB MICs ranged from 1.0 to 2.0 mg/L, 0.06 to >16 mg/L and 2.0 to >32 mg/L, respectively. There was one isolate for which only L-AMB given at 10 mg/kg/day was effective; broth dilution MICs of AMB and L-AMB were 0.5 mg/L, while the Etest MIC of AMB was 2.0 mg/L. CONCLUSIONS: Our data indicate that not all isolates of A. flavus should be considered resistant to AMB. The Etest represented the in vitro method that best correlated with the experimental infection. Finally, a clinical isolate showing an MIC ≥2.0 mg/L may be reasonably considered resistant in vivo to any dose/formulation of the polyene.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Aspergilosis/microbiología , Aspergillus flavus/efectos de los fármacos , Farmacorresistencia Fúngica , Polienos/uso terapéutico , Administración Intravenosa , Animales , Aspergillus flavus/aislamiento & purificación , Modelos Animales de Enfermedad , Femenino , Ratones , Pruebas de Sensibilidad Microbiana , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Invasive fungal disease by Candida spp. is on the rise in the modem era of prolonged patient survival by virtue of improved critical care measures, novel chemotherapy regimens, and increasing immunosuppression following organ transplants. Invasive candidiasis (IC) in the setting of an intensive care unit results in prolonged hospital stay and increased morbidity. Clinical suspicion plays a major role in the diagnosis of IC, as current laboratory methods are not very sensitive. Various serum markers and molecular techniques are under development to improve diagnostic strategies. Treatment options involve an expanding spectrum of antifungals. Knowledge of local epidemiology and the risk factors that predispose patients to this disease are essential for effective patient care in an intensive care setting.
Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis/terapia , Cuidados Críticos/métodos , Infección Hospitalaria/terapia , Fungemia/terapia , Algoritmos , Azoles/uso terapéutico , Biomarcadores , Candidiasis/diagnóstico , Candidiasis/epidemiología , Candidiasis/microbiología , Quimioprevención , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/epidemiología , Infección Hospitalaria/microbiología , Árboles de Decisión , Equinocandinas/uso terapéutico , Flucitosina/uso terapéutico , Fungemia/diagnóstico , Fungemia/epidemiología , Médicos Hospitalarios/métodos , Humanos , Unidades de Cuidados Intensivos , Pruebas de Sensibilidad Microbiana , Morbilidad , Selección de Paciente , Polienos/uso terapéutico , Factores de Riesgo , Sensibilidad y EspecificidadRESUMEN
The incidence of systemic fungal infections that has risen dramatically over the past three decades has propelled a continuous need for more potent antifungal drugs. The purpose of this research was to evaluate the chemotherapeutic activity of a new heptaene polyene macrolide antibiotic (SJA-95) and liposomal incorporated SJA-95 (lip. SJA-95) in a mouse model of aspergillosis and cryptococcosis respectively. Lip. SJA-95 was prepared in our laboratory by the proliposome method involving incorporation of the antifungal into the proliposome mixture and its subsequent conversion into a liposomal dispersion by a simple dilution step. Treatment with free SJA-95 and lip. SJA-95, both in aspergillosis and cryptococcosis, progressively prolonged the survival time and decreased the fungal loads in vital organs respectively. A higher LD(50) value of lip. SJA as compared to that of free SJA-95 was indicative of reduced toxicity of lip. SJA-95. Our findings suggest lip. SJA-95 treatment results in prolonged survival time, effective microbiological clearance and reduced toxicity that might help to establish its usefulness as a chemotherapeutic agent in systemic fungal infections with fewer adverse reactions.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Criptococosis/tratamiento farmacológico , Fungemia/tratamiento farmacológico , Macrólidos/uso terapéutico , Polienos/uso terapéutico , Animales , Antifúngicos/administración & dosificación , Antifúngicos/toxicidad , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/aislamiento & purificación , Encéfalo/microbiología , Cryptococcus neoformans/efectos de los fármacos , Cryptococcus neoformans/aislamiento & purificación , Evaluación Preclínica de Medicamentos , Riñón/microbiología , Dosificación Letal Mediana , Recuento de Leucocitos , Liposomas/administración & dosificación , Hígado/microbiología , Pulmón/microbiología , Macrólidos/administración & dosificación , Macrólidos/toxicidad , Ratones , Polienos/administración & dosificación , Polienos/toxicidad , Bazo/microbiologíaRESUMEN
Full healing was achieved within eight weeks in a malignant fungating wound using the principles of the TIME paradigm. This concept appears to provide a structured and systematic approach for managing such non-healing wounds.
Asunto(s)
Neoplasias de la Mama/patología , Cuidados de la Piel/métodos , Neoplasias Cutáneas/prevención & control , Cicatrización de Heridas , Infección de Heridas/prevención & control , Adulto , Vendas Hidrocoloidales , Carboximetilcelulosa de Sodio/uso terapéutico , Protocolos Clínicos , Combinación de Medicamentos , Exudados y Transudados , Femenino , Gelatina/uso terapéutico , Humanos , Humedad , Control de Infecciones , Inflamación , Metronidazol/uso terapéutico , Evaluación en Enfermería , Odorantes , Cuidados Paliativos/métodos , Selección de Paciente , Pectinas/uso terapéutico , Polienos/uso terapéutico , Derivación y Consulta , Cuidados de la Piel/instrumentación , Cuidados de la Piel/enfermería , Neoplasias Cutáneas/secundario , Infección de Heridas/etiologíaRESUMEN
OBJECTIVE: Stomahesive skin-protection powder has been reported to be useful as a skin-care and skin-barrier product for the management of stomas. This study aimed to evaluate its efficacy, in terms of wound healing, moisture retention and pain management, as an alternative to conventional dressing materials. Both clinical and animal studies were undertaken. METHOD: The efficacy of the Stomahesive powder was tested by measuring the thickness of granulation tissue formed in a total skin defect in a db/db mouse model. We then compared the healing process using either the skin-protection powder or a conventional film dressing material. In the clinical study 17 patients with various intractable ulcers were treated with Stomahesive powder, and healing was evaluated. RESULTS: In the mouse model, granulation tissue in the wounds treated with the powder was 2.86 times thicker than that of the wounds treated with the film dressing. In the clinical study, 16 out of 17 wounds healed completely. CONCLUSION: The Stomahesive powder could be an effective treatment modality for contact ulceration, superficial ulcers with complex contours and morphology, and superficial ulcers contaminated by liquid faeces or vaginal discharge that have not responded to conventional dressings. DECLARATION OF INTEREST: None.
Asunto(s)
Carboximetilcelulosa de Sodio/uso terapéutico , Modelos Animales de Enfermedad , Gelatina/uso terapéutico , Apósitos Oclusivos/normas , Pectinas/uso terapéutico , Polienos/uso terapéutico , Úlcera Cutánea/terapia , Administración Cutánea , Anciano , Anciano de 80 o más Años , Animales , Carboximetilcelulosa de Sodio/farmacología , Combinación de Medicamentos , Evaluación de Medicamentos , Femenino , Gelatina/farmacología , Tejido de Granulación/efectos de los fármacos , Humanos , Masculino , Ratones , Ratones Endogámicos , Persona de Mediana Edad , Pectinas/farmacología , Polienos/farmacología , Polvos , Cuidados de la Piel , Úlcera Cutánea/etiología , Úlcera Cutánea/patología , Estadísticas no Paramétricas , Cicatrización de HeridasRESUMEN
A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Candidiasis/tratamiento farmacológico , Antifúngicos/efectos adversos , Aspergilosis/epidemiología , Azoles/uso terapéutico , Candidiasis/epidemiología , Ensayos Clínicos como Asunto , Quimioterapia Combinada , Equinocandinas , Proteínas Fúngicas/uso terapéutico , Humanos , Péptidos Cíclicos/uso terapéutico , Polienos/uso terapéutico , Suiza/epidemiologíaRESUMEN
Invasive fungal infections pose major management problems for clinicians caring for hematopoietic cell transplant patients. Two major fungal genera, Candida and Aspergillus, account for most fungal infections. Rates of systemic Candida infection range from 15% to 25%, mostly in the pre-engraftment period. Prophylaxis by fluconazole has dramatically reduced the frequency of early Candida infections. Caspofungin has recently been shown to offer an excellent alternative to amphotericin B (with less toxicity) or fluconazole (with a broader spectrum) for therapy of systemic Candida infections. Aspergillus infections occur in 15% to 20% of allogeneic hematopoietic cell transplant patients, most frequently in the post-engraftment period; they are associated with a severe diminution of cell-mediated immune responses by graft-versus-host disease and prolonged corticosteroid use. Voriconazole, a recently introduced broad-spectrum azole, has excellent activity against Aspergillus and is generally well tolerated. Voriconazole currently offers the best prospect for success and tolerance as a first-line treatment for aspergillosis. Second-line therapies include lipid formulations of amphotericin B, caspofungin, or intravenous itraconazole. Unfortunately, early initiation of therapy for aspergillosis is frequently not possible because of inaccurate diagnostics. One new diagnostic, the galactomannan assay, has recently been approved, and others are in development; these offer promise for earlier diagnosis without the need for invasive procedures. It is hoped that these new therapies and new diagnostics will usher in a new era of antifungal therapy.
Asunto(s)
Antifúngicos/uso terapéutico , Proteínas Fúngicas , Péptidos Cíclicos , Antifúngicos/clasificación , Antifúngicos/farmacocinética , Azoles/efectos adversos , Azoles/farmacocinética , Azoles/uso terapéutico , Equinocandinas , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Micosis/diagnóstico , Micosis/tratamiento farmacológico , Micosis/etiología , Nucleósidos/efectos adversos , Nucleósidos/farmacocinética , Nucleósidos/uso terapéutico , Péptidos/efectos adversos , Péptidos/farmacocinética , Péptidos/uso terapéutico , Polienos/efectos adversos , Polienos/farmacocinética , Polienos/uso terapéuticoRESUMEN
The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal. Previously there were only 2 antifungals with activity against Aspergillus, but over the last few years there has been an explosion of newer agents and reformulations of older antifungals. Exploration has also begun with immunotherapy, with use of cytokines and granulocyte transfusions alone or in combination with antifungal therapy. This review will detail the available in vitro, in vivo, and clinical experience with the newer antifungal and immunomodulatory therapies in development for treatment of invasive aspergillosis.
Asunto(s)
Aminoglicósidos , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Antifúngicos/clasificación , Aspergilosis/terapia , Azoles/clasificación , Azoles/uso terapéutico , Química Farmacéutica , Citocinas/uso terapéutico , Farmacorresistencia Microbiana , Quimioterapia Combinada , Granulocitos/inmunología , Humanos , Inmunoterapia , Pruebas de Sensibilidad Microbiana , Polienos/clasificación , Polienos/uso terapéuticoRESUMEN
The studies presented were designed to test the efficacy of farnesyltransferase inhibitors (FTIs) as potential chemopreventive compounds in the mouse lung tumor model, and in tumor cell lines. The compounds included manumycin, gliotoxin, dihydroepiandrosterone (DHEA), perillyl alcohol (POH), and FTI-276. Each of these compounds had the potential, based on in vitro and limited in vivo evidence, to inhibit mouse lung tumorigenesis. In vitro studies were conducted with both K-ras-transformed NIH-3T3 cells and mouse lung tumor epithelial cell lines. We utilized 2 primary mouse lung tumor models that reliably produce lung tumors with an oncogenic K-ras mutation when induded by 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK). Manumycin, gliotoxin, DHEA, and POH were administered 3 times per week peritoneally (i.p.), starting 1 week prior to carcinogen treatment, and throughout the test period (4.5 months). FTI-276 was delivered daily for 4 months by a time-release pellet method. Both the manumycin and gliotoxin treatment groups demonstrated 100% incidence and an increase in tumor multiplicity over control, of 66% and 58% increase respectively (P < .05). Although DHEA showed no significant chemopreventive effect, POH treatment demonstrated a 22% reduction in tumor incidence (P < .05) and a 58% reduction in tumor multiplicity (P < .05). Finally, FTI-276 reduced both the tumor multiplicity by 41.7% (P < .005), and the total tumor volume/burden per mouse by 79.4% (P < .0001). The apoptotic index in FTI-276-treated tumors showed an increase of 77% over control tumors (P < .05). In vitro, all compounds demonstrated growth inhibition at a dose-response manner; however, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses. In summary, we have shown that POH and FTI-276 are chemopreventive in a primary mouse lung tumor model. In contrast, DHEA was not significantly chemopreventive at the dosage utilized, and treatment of an immunocompetent host with manumycin or gliotoxin demonstrated a significant increase in tumorigenicity over carcinogen control.
Asunto(s)
Adenoma/prevención & control , Transferasas Alquil y Aril/antagonistas & inhibidores , Inhibidores Enzimáticos/uso terapéutico , Neoplasias Pulmonares/prevención & control , Metionina/análogos & derivados , Monoterpenos , Células 3T3 , Adenoma/inducido químicamente , Adenoma/química , Adenoma/patología , Animales , Apoptosis , Quimioprevención , ADN de Neoplasias/análisis , Deshidroepiandrosterona/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Farnesiltransferasa , Técnica del Anticuerpo Fluorescente Indirecta , Gliotoxina/uso terapéutico , Etiquetado Corte-Fin in Situ , Neoplasias Pulmonares/inducido químicamente , Neoplasias Pulmonares/química , Neoplasias Pulmonares/patología , Metionina/uso terapéutico , Ratones , Ratones Endogámicos A , Ratones Endogámicos C3H , Polienos/uso terapéutico , Reacción en Cadena de la Polimerasa , Alcamidas Poliinsaturadas , Antígeno Nuclear de Célula en Proliferación/análisis , Terpenos/uso terapéuticoRESUMEN
BACKGROUND: Neutrophils may play an important role in the development of liver ischemia/reperfusion injury. We investigated the effects of the immunosuppressants azathioprine (AZA), cyclosporine A (CsA), tacrolimus (FK506), and rapamycin (RPM) on the expression of cytokine-induced neutrophil chemoattractant (CINC) after ischemia/reperfusion of the liver. METHODS: Liver ischemia was induced in male Wistar rats by occluding the portal vein with a microvascular clip for 30 minutes. Rats received two intramuscular injections of AZA (4 mg/kg), CsA (5 mg/kg), FK506 (0.5 mg/kg), or RPM (0.5 mg/kg) 3 and 24 hours before ischemia/reperfusion of the liver. RESULTS: Serum CINC concentrations in untreated animals increased, peaked 6 hours after reperfusion, and thereafter decreased gradually. Pretreatment with AZA, CsA, FK506, and RPM, however, inhibited the increase in serum CINC concentrations after reperfusion. CINC mRNA in liver tissue increased and peaked 3 hours after reperfusion, but was significantly lower in animals treated with AZA, CsA, FK506, and RPM. In vitro CINC production by Kupffer cells harvested from animals treated with AZA, CsA, FK506, or RPM 3 hours after reperfusion was also significantly lower than that observed in untreated animals. Both myeloperoxidase activity and the number of neutrophils accumulating in the liver 24 hours after reperfusion in animals treated with AZA, CsA, FK506, and RPM were significantly lower than in untreated animals. This correlated with lower serum aspartate transaminase, alanine transaminase, and lactate dehydrogenase levels in animals treated with AZA, CsA, FK506, and RPM 24 hours after reperfusion. CONCLUSION: The immunosuppressants AZA, CsA, FK506, and RPM reduce neutrophil accumulation and attenuate ischemia/reperfusion injury of the liver.
Asunto(s)
Inmunosupresores/uso terapéutico , Interleucina-16/metabolismo , Hígado/irrigación sanguínea , Neutrófilos/efectos de los fármacos , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/inmunología , Animales , Azatioprina/uso terapéutico , Ciclosporina/uso terapéutico , Evaluación Preclínica de Medicamentos , Inmunosupresores/inmunología , Interleucina-16/inmunología , Masculino , Neutrófilos/inmunología , Polienos/uso terapéutico , Ratas , Ratas Wistar , Daño por Reperfusión/metabolismo , Sirolimus , Tacrolimus/uso terapéutico , Factores de TiempoAsunto(s)
Carboximetilcelulosa de Sodio/uso terapéutico , Cateterismo Venoso Central/enfermería , Catéteres de Permanencia , Dermatitis/enfermería , Gelatina/uso terapéutico , Pectinas/uso terapéutico , Polienos/uso terapéutico , Adhesivos Tisulares/efectos adversos , Combinación de Medicamentos , HumanosRESUMEN
Roseofungin, a pentaen was used as an example in investigation of certain characteristics of inactivation of polyenic antibiotics. An inactivation product of the antibiotic having no antiviral or antimycotic activity was isolated by TLC and column chromatography on Sefadex LH-20. UV, IR and EPR spectroscopy showed that this product was cys-tetraen without conjugation of the lactone carbonyl to the polyenic system.
Asunto(s)
Antibacterianos/antagonistas & inhibidores , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antifúngicos/antagonistas & inhibidores , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Virus del Sarcoma Aviar/efectos de los fármacos , Embrión de Pollo , Evaluación Preclínica de Medicamentos , Virus de la Influenza A/efectos de los fármacos , Ratones , Infecciones por Orthomyxoviridae/tratamiento farmacológico , Polienos/antagonistas & inhibidores , Polienos/farmacología , Polienos/uso terapéutico , Virus Vaccinia/efectos de los fármacosAsunto(s)
Infecciones Bacterianas/tratamiento farmacológico , Clotrimazol/uso terapéutico , Imidazoles/uso terapéutico , Mepartricina/uso terapéutico , Polienos/uso terapéutico , Enfermedades Vaginales/tratamiento farmacológico , Adulto , Clotrimazol/administración & dosificación , Tolerancia a Medicamentos , Femenino , Humanos , Mepartricina/administración & dosificación , Persona de Mediana Edad , Enfermedades Vaginales/etiologíaRESUMEN
Clear antiviral activity of carbonyl-conjugated pentaene macrolides, such as flavofungin, mycothicin, brunefungin and flavopentin was shown on models with infectious and oncogenic viruses. The antibiotics were active against influenza A and B virus. The effect was most pronounced in the in vitro and in ovo systems. On a model of experimental influenza infection of mice with the lethal outcome, antiinfluenzal activity of flavofungin was comparable to that of remantadin. However, unlike the latter one flavofungin and brunefungin inhibited the growth of influenza B virus. The drugs had a pronounced inhibitory effect on variolavaccine virus and prevented formation of foci of cell neoplastic transformation infected with various strains of Rous sarcoma virus.
Asunto(s)
Antibacterianos/farmacología , Antivirales/farmacología , Polienos/farmacología , Animales , Antibacterianos/uso terapéutico , Antivirales/uso terapéutico , Virus del Sarcoma Aviar/efectos de los fármacos , Embrión de Pollo , Evaluación Preclínica de Medicamentos , Ratones , Orthomyxoviridae/efectos de los fármacos , Infecciones por Orthomyxoviridae/tratamiento farmacológico , Polienos/uso terapéutico , Factores de Tiempo , Virus Vaccinia/efectos de los fármacosAsunto(s)
Hiperplasia Prostática/tratamiento farmacológico , Antagonistas Adrenérgicos alfa/uso terapéutico , Bromocriptina/uso terapéutico , Ciproterona/uso terapéutico , Caproato de Gestonorona/uso terapéutico , Humanos , Masculino , Medrogestona/uso terapéutico , Megestrol/uso terapéutico , Extractos Vegetales/uso terapéutico , Polienos/uso terapéutico , Espironolactona/uso terapéutico , Tamoxifeno/uso terapéuticoRESUMEN
Mycoheptin, an original antifungal polyenic antibiotic is a complex of several heptaen components. 2 heptaen components designated as mycoheptins A1 and A2 were isolated from the mycoheptin complex with the counter-current distribution technique in a system of methanol-chloroform-forate buffer, pH 8.3 (2:2:1). It was found that component A2 was the main one. Its content in the preparation is at least 80 per cent. The components were studied comparatively with respect to the elemental composition, UV and IR spectra, distribution coefficients in different solvent systems, specific rotation, biological activity and acute toxicity. Both components are original in the subgroup of "nonaromatic" heptaens. Mycoheptin A1 has a lower biological activity and toxicity but its chemotherapeutic efficiency is higher.